# Avalon GloboCare Corp. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Avalon GloboCare Corp.). ## Overview Avalon GloboCare Corp. is a U.S.-based company with two distinct operating themes: early-stage life sciences commercialization and income-producing real estate. In its recent filings, the company describes research and development work around MIT-linked protein design and CAR-T related intellectual property, alongside commercialization of the KetoAir breathalyzer for ketosis monitoring. It also generates rental revenue from an income-producing property in New Jersey, which provides a separate operating cash flow stream. The business remains development-stage and capital constrained, with management explicitly warning about going concern risk and the need for additional financing. ## Products & services • KetoAir breathalyzer and related commercialization • Exclusive distribution of KetoAir in North America, South America, EU and UK • R&D and patent development with MIT-linked protein design • CAR-T cellular therapy intellectual property development • Income-producing real estate rental in New Jersey - **Consumer health device commercialization** (40%) — KetoAir breathalyzer products and related direct-to-consumer commercialization for ketosis monitoring. - **Life sciences R&D and IP development** (20%) — Patent filings, sponsored research, and co-development work tied to MIT and CAR-T technologies. - **Real estate rental income** (40%) — Rental revenue from the company's income-producing property in New Jersey. - KetoAir breathalyzer and related commercialization - Exclusive distribution of KetoAir in North America, South America, EU and UK - R&D and patent development with MIT-linked protein design - CAR-T cellular therapy intellectual property development - Income-producing real estate rental in New Jersey ## Customers Avalon GloboCare's commercial customers appear to be consumers and patients interested in ketosis monitoring, especially in the diabetes and obesity markets. The company sells KetoAir through its website and social media, indicating a direct-to-consumer motion rather than a traditional hospital or distributor-led channel. On the life sciences side, the value proposition is more indirect: the company is building intellectual property that could be licensed, partnered, or further developed rather than sold as a finished product today. Its real estate activity serves tenants at the New Jersey property, creating a separate customer base for rental income. Because the company is still early in commercialization, customer demand and adoption are concentrated in a few narrow use cases. - **Direct-to-consumer KetoAir buyers** (primary) — Individuals purchasing the KetoAir breathalyzer online for ketosis monitoring and personal health tracking. - **Diabetes and obesity market users** (primary) — Health-conscious consumers and patients targeted because the device is positioned for ketosis-related monitoring in these end markets. - **Real estate tenants** (secondary) — Occupants of the New Jersey property who generate rental revenue for the company. - **Potential IP partners** (emerging) — Biotech or therapeutic partners that could license or collaborate on MIT-linked protein design and CAR-T intellectual property. - Consumers seeking ketosis monitoring for diet and wellness use - People managing diabetes or obesity who may use KetoAir as a tracking tool - Website and social-media buyers reached directly by the company - Potential future licensing or development partners for MIT-linked IP - Tenants of the New Jersey income-producing real estate property ## Geography The company is headquartered in the United States and maintains cash primarily in U.S. financial institutions, with a small balance held in China. Its operating disclosures point to a New Jersey real estate asset as a current source of rental revenue, making the U.S. the core operating geography. The KetoAir distributorship covers North America, South America, the EU, and the UK, so commercialization is intended to reach multiple international markets even though current selling channels are digital. The company also references China in its cash holdings and tax discussion, which suggests some administrative or legacy exposure there. Because the business is small and capital constrained, geography matters mainly through where revenue can be generated and where cash, legal, and tax obligations sit. - United States is the main operating base and cash location - New Jersey property generates rental revenue in the U.S. - KetoAir distribution rights cover North America, South America, EU and UK - Small cash balance is held in China, indicating limited foreign exposure - International commercialization is relevant to future growth, not yet scale ## Strategy Avalon GloboCare's near-term strategy is to commercialize KetoAir while continuing to advance its life sciences intellectual property portfolio. Management is trying to convert the MIT-linked protein design work and CAR-T patent filings into protectable assets that could support future partnering or monetization. At the same time, the company is relying on rental income from its New Jersey property to help fund operations, showing that it is using a mixed model to bridge development-stage cash needs. The filings make clear that capital raising is central to execution, since the company expects current cash to be insufficient and plans to raise equity or debt. In practical terms, the strategy is about preserving optionality: keep the real estate cash flow, build product commercialization, and maintain enough funding to continue R&D and IP development. - **KetoAir commercialization** (short-term) — The company needs a sellable product with near-term revenue potential to reduce dependence on financing. - **Advance patent portfolio** (medium-term) — Protectable IP can create future licensing, partnership, or valuation upside even before product revenue scales. - **Maintain liquidity through financing and rental income** (short-term) — The company has recurring losses and a going concern warning, so funding continuity is essential. - Commercialize KetoAir through direct online channels - Target diabetes and obesity use cases for ketosis monitoring - Advance MIT-linked patent applications and protein design IP - Continue CAR-T related intellectual property development - Use New Jersey rental income to support liquidity - Raise additional capital through equity or debt financing ## Risks The most immediate risk is liquidity and going concern pressure, because management states that current cash will not cover operating expenses for the next twelve months without additional financing. The company also depends on a narrow set of revenue sources, including rental income and early-stage KetoAir sales, so commercialization delays or weak consumer adoption would quickly affect cash flow. Its life sciences programs are still at the patent and laboratory validation stage, which means technical, regulatory, and partnering risk remain high before any meaningful monetization. As a small issuer, Avalon is also exposed to dilution risk if it funds operations through repeated equity raises, and debt-related accounting items can create volatility in reported results. More broadly, consumer health device demand, competitive pressure in wellness monitoring, and changes in U.S. capital markets all matter because the business model requires both product traction and external funding. - **Going concern and liquidity shortfall** [critical] — Management states current cash is insufficient to cover operating expenses for the next twelve months and additional financing is required. - **Financing and dilution risk** [high] — The company expects to raise capital through equity or debt, which may be unavailable or highly dilutive. - **Commercialization risk for KetoAir** [high] — Sales depend on consumer adoption of a niche ketosis-monitoring device and effective online marketing. - **Early-stage R&D and IP monetization risk** [medium] — MIT-linked and CAR-T programs are still in development, so patent or partnership value may not materialize. - **Interest and derivative volatility** [medium] — Convertible debt, debt discounts, and derivative liabilities can create large non-operating swings in reported results. - Going concern risk due to insufficient cash to fund the next 12 months - Dependence on equity or debt financing, which can cause dilution - Limited revenue base concentrated in KetoAir sales and one rental property - Early-stage IP may never become commercialized or licensed - Consumer adoption risk in the diabetes and obesity monitoring market - Competitive and regulatory risk in health-related devices - Interest expense and derivative accounting can add earnings volatility ## Accounting Avalon's accounting profile is shaped by a mix of real estate rental accounting, early-stage product commercialization, and complex financing instruments. Rental income is accounted for under lease accounting rather than ASC 606, while straight-line recognition affects the timing of reported revenue versus contractual cash receipts. The company also highlights significant estimates around real estate useful lives, intangible assets, impairment testing, stock-based compensation, deferred tax asset valuation allowances, and the fair value of warrants and embedded conversion features. These judgments matter because the company has recurring losses, so small changes in assumptions can materially affect reported earnings, asset values, and equity. In addition, debt discount amortization, extinguishment losses, and derivative fair value changes have already driven large swings in other expense and net loss. - **Lease accounting for rental income** — Revenue timing and rent receivables - **Fair value of warrants and embedded conversion features** — Non-operating income/expense and balance sheet liabilities - **Impairment and useful life estimates** — Asset carrying values and future depreciation/amortization - **Deferred tax asset valuation allowance** — Income tax expense and equity - Rental revenue is recognized under lease accounting, not ASC 606 - Straight-line rent recognition can differ from cash collected - Real estate and intangible asset impairment judgments affect asset values - Deferred tax asset valuation allowances depend on future profitability assumptions - Warrants and embedded conversion features require fair value estimates - Debt discount amortization and extinguishment losses can distort non-operating results - Stock-based compensation is sensitive to valuation assumptions --- *Last updated: 2026-08-11T04:46:21.782406+00:00*